Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia (ALADIN)

Background. Cancer is the leading cause of death by disease in children. Most pediatric tumors differ from adult tumors in terms of biological and clinical characteristics. In children, the part of genetic determinism could be higher since the role of environmental factors may be less pronounced than in adults and that a young age at onset is a main feature of genetic cancer predisposition. Recent studies suggested that a number of genetic predisposition remains to be characterized.

Methods. Trio-Based whole exome sequencing of germline DNA from patients (children and adults diagnosed with cancers between 0 and 17 years) and parents will be performed prospectively in a multicentric study including 40 unselected cases of malignant tumor. Participating hospitals will include the CHU of Montpellier, the CHU de Nice and the AP-HP. Tumor analysis will include whole exome analysis and transcriptome for the identification of therapeutic target and contribute to confirm potential link between constitutive mutations and tumor phenotype (such as loss of expression, loss of heterozygosity).

Perspectives. This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: Solid Tumor, Childhood; Pediatric Tumor; Familial Cancer; Hematological Tumor
• Intervention / Treatment: Genetic: Exome sequencing in pediatrics cancers

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Occitanie
    • Montpellier, Occitanie, France, 34295
      • CHU Montpellier

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The patient has a solid or haematological malignancy, either familial forms or isolated cases diagnosed between the ages of 0 and 17 years.
• The minor patient and both biological parents are available to participate in the study OR
• The adult patient and one or both parents are available to participate in the study.
• The patient's parents must have given their free and informed consent and signed the consent for the minor's participation in the study.
• The patient's parent(s) must have given free and informed consent and the patient of legal age must have signed the consent for participation in the study.
• The patient must be affiliated or beneficiary of a Frrench social security scheme.

Exclusion Criteria:

• The patient's parents are under guardianship or trusteeship or under legal protection Yes No
• Failure to obtain written informed consent from parents (for themselves and their minor child) after a period of reflection Yes No
• No affiliation to or beneficiary of a French social security scheme (for biological parents and the patient)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Children with cancer (Proband) with theirs parents	Genetic: Exome sequencing in pediatrics cancers; This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of genetic variants and confirmation of the causality of these variants for the patient's pathology whole exome sequencing	A blood sample will be taken from patients and their parents in order to carry out genetic analyses. New generation NGS Exome sequencing in trio (patient and 2 healthy parents) on an Illumina HiSeq 2000 platform using the SureSelectXT Human All Exon 50Mb, V5 kit. Bioinformatics analysis of the data. Confirmation of mutations by Sanger sequencing (gold standard). In case of identification of mutations in candidate genes confirmed by Sanger sequencing, we will perform functional and clinical-genetic studies.	12 months

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Collaborators: Soroptimist association of Monaco
• Investigators: Principal Investigator: Pascal Pujol, PU-PH, Montpellier University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 9, 2020
• Primary Completion (Actual): February 12, 2025
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: July 10, 2020
• First Submitted That Met QC Criteria: July 10, 2020
• First Posted (Actual): July 15, 2020

Study Record Updates

• Last Update Posted (Estimated): September 30, 2025
• Last Update Submitted That Met QC Criteria: September 26, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: Pediatric oncology; Transcriptome; Exome based trio; Cancer predisposition gene; Target therapies; Tumor exome
• Additional Relevant MeSH Terms: Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms; Hematologic Neoplasms; Investigative Techniques; Genetic Techniques; Sequence Analysis; Sequence Analysis, DNA; Whole Genome Sequencing; Exome Sequencing
• Other Study ID Numbers: RECHMPL19_0519; 2020-A0298-31 (Other Identifier: IDRCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No